쥐의 활동 기반 거식 증을 평가

Executive Industry Relevance

The activity-based anorexia (ABA) model in mice provides a translational system to investigate neurobehavioral mechanisms underlying anorexia nervosa, a disorder with high unmet medical need. By enabling controlled study of feeding behavior and hyperactivity phenotypes, the model supports target validation and mechanistic de-risking in early discovery. This facilitates hypothesis-driven screening for novel therapeutic candidates affecting appetite regulation and reward pathways.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses related to feeding behavior and activity regulation in a disease-relevant system.
• Operational Value: Supports biological de-risking by isolating neural and behavioral contributors to anorexia-like phenotypes.
• Predictive Value: Enhances confidence in target engagement through quantifiable outputs such as food intake and wheel running activity.

Screening & Assay Development

• Scientific Value: Provides a standardized, quantifiable phenotypic readout for compound screening affecting energy balance and motivation.
• Operational Value: Enables assay reproducibility through precise monitoring of food consumption and wheel rotations via connected software.
• Scalability: Facilitates longitudinal tracking across restriction and baseline phases for dose-response evaluation.

Translational & Preclinical Research

• Scientific Value: Aligns with disease relevance by modeling key behavioral features of anorexia nervosa, including reduced caloric intake and increased activity.
• Operational Value: Supports translational continuity from discovery through preclinical validation using measurable behavioral endpoints.
• Risk Mitigation: Informs risk-adjusted advancement decisions by identifying compounds that normalize aberrant behavior without inducing excessive weight loss.

Pipeline & Workflow Integration

The ABA model fits within the discovery continuum from target hypothesis testing to lead identification, particularly for CNS-active compounds affecting homeostatic and reward circuits.

• Discovery Biology: Supports hypothesis testing of neural circuits involved in appetite and motivation, such as those involving BDNF and NCAM1 pathways.
• Screening: Delivers quantitative, time-series data on food intake and locomotor activity, enabling reliable compound evaluation.
• Analytics: Generates measurable dependent variables (e.g., grams of food consumed, wheel revolutions) that allow statistical comparison across experimental groups.
• Translational Research: Connects behavioral outputs to neurochemical changes, supporting biomarker alignment in preclinical studies.
• Enterprise Reuse: Represents a reusable behavioral platform adaptable across strains and genetic models for target validation and mechanism of action studies.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence by modeling a face-valid anorexia-like state driven by ethologically relevant conditions.
• Operational Value: Ensures standardization through protocolized feeding schedules, wheel access, and automated data acquisition.
• Strategic Value: Improves go/no-go decisions by reducing ambiguity in behavioral phenotypes linked to eating disorder pathophysiology.
• Portfolio Impact: Enables risk-adjusted prioritization of compounds based on normalization of ABA phenotypes, reducing late-stage biological attrition.

Implementation Considerations

• Requires expertise in behavioral neuroscience, rodent handling, and automated monitoring systems.
• Dependent on instrumentation including running wheels with magnetic sensors, wireless hubs, and data acquisition software.
• Necessitates cross-team standardization of feeding protocols, weighing procedures, and wheel maintenance to ensure data integrity.
• Involves adaptation considerations across mouse strains, as baseline activity and feeding behaviors may vary.
• Includes practical limitations such as stress from handling, technical issues in wheel tracking, and the need for consistent timing of measurements.

Biopharma FAQs